Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aestus Therapeutics has developed a proprietary systems biology platform to identify novel drug targets and repurpose compounds for neurological diseases. Its lead program, ATx08‑001, a selective PPAR modulator, completed a Phase 2 trial in postherpetic neuralgia. The company also holds rights to additional clinical-stage assets and collaborates with ALS Therapy Development Institute on ALS therapies. Early clinical results support further development of its pipeline for unmet needs in neuropathic pain and neurodegenerative disorders.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aestus Therapeutics.